Basit öğe kaydını göster

dc.contributor.authorBurcak, GÜLDEN
dc.contributor.authorGelisgen, R.
dc.contributor.authorSeven, A.
dc.contributor.authorCivelek, S.
dc.contributor.authorAndican, G.
dc.contributor.authorKucuk, S. H.
dc.contributor.authorOzdogan, M.
dc.date.accessioned2021-03-04T08:19:49Z
dc.date.available2021-03-04T08:19:49Z
dc.date.issued2010
dc.identifier.citationCivelek S., Gelisgen R., Andican G., Seven A., Kucuk S. H. , Ozdogan M., Burcak G., "Advanced glycation end products and antioxidant status in nondiabetic and streptozotocin induced diabetic rats: effects of copper treatment", BIOMETALS, cilt.23, sa.1, ss.43-49, 2010
dc.identifier.issn0966-0844
dc.identifier.othervv_1032021
dc.identifier.otherav_62c256a6-56a0-4625-9f5b-3072d0ed4a7f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/68769
dc.identifier.urihttps://doi.org/10.1007/s10534-009-9265-9
dc.description.abstractThe effects of Cu(II) supplementation on glycemic parameters, advanced glycation end products (AGEs), antioxidant status (glutathione; GSH and total antioxidant capacity; TAOC) and lipid peroxidative damage (thiobarbituric acid-reactive substances, TBARS) were investigated in streptozotocin (STZ) induced diabetic rats. The study was carried out on Wistar albino rats grouped as control (n = 10), CuCl2 treated (n = 9), STZ (n = 10) and STZ,CuCl2 treated (n = 9). STZ was administered intraperitoneally at a single dose of 65 mg/kg and CuCl2, 4 mg copper/kg, subcutaneously, every 2 days for 60 days. At the end of this period, glucose(mg/dl), Cu(mu g/dl), TBARS(mu mol/l), TAOC(mmol/l) were measured in plasma, GSH(mg/gHb) in erythrocytes and glycated hemoglobin (GHb)(%) in blood. Plasma AGE-peptides(%) were measured by HPLC flow system with spectrofluorimetric and spectrophotometric detectors connected on-line. Data were analyzed by the non-parametric Kruskal-Wallis and Mann-Whitney U test. In the STZ group glucose, GHb and AGE-peptide levels were all significantly higher than the control group (P < 0.01, P < 0.05, and P < 0.01, respectively). CuCl2 treated group had significantly lower glucose but significantly higher GHb, TAOC and TBARS levels than the control group (P < 0.05, P < 0.001, P < 0.05 and P < 0.001, respectively). STZ,CuCl2 treated group had significantly higher GHb, TAOC and TBARS levels compared with the control group (P < 0.001, P < 0.05 and P < 0.05, respectively); but only TAOC level was significantly higher than the STZ group (P < 0.01). This experimental study provides evidence that copper intake increases total antioxidant capacity in both nondiabetic and diabetic states. However despite the potentiated antioxidant defence, lipid peroxidation and glycation enhancing effects of CuCl2 are evident under nondiabetic conditions.
dc.language.isoeng
dc.subjectTemel Bilimler
dc.subjectSitogenetik
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectYaşam Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.titleAdvanced glycation end products and antioxidant status in nondiabetic and streptozotocin induced diabetic rats: effects of copper treatment
dc.typeMakale
dc.relation.journalBIOMETALS
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume23
dc.identifier.issue1
dc.identifier.startpage43
dc.identifier.endpage49
dc.contributor.firstauthorID2575


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster